No data are available on the hypothesis that SGLT2i could have delayed initiating insulin by preserving beta cell mass and function in patients affected by MODY, even though in both animal models and individuals with type 2 diabetes or prediabetes, SGLT2i as a class seem to exert a role in ameliorating insulin sensitivity and secretion [9]. The gene discussed is INS; the disease is MODY.